<DOC>
	<DOC>NCT01364662</DOC>
	<brief_summary>This will be a randomized, double-blind, placebo-controlled, dose-ranging, efficacy and safety study in children with impulsive aggression comorbid with Attention-Deficit/Hyperactivity Disorder (ADHD). The target subjects are healthy male and female children aged 6 to 12 years, inclusive, with a diagnosis of ADHD. A total of 120 subjects will be randomized across approximately 30 US centers to one of four treatment groups.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<criteria>1. Healthy pediatric male or female subjects, age 6 to 12 years. 2. Diagnostic and Statistical Manual of Mental Disorders IV Text Revision (DSMIVTR) diagnosis of ADHD. 3. RMOAS score &gt;=24 at screening and RMOAS score &gt;=20 for randomization 4. IQ greater than 71. 5. Weight of &gt;=20kg 6. current treatment with psychostimulant (1 month prior to screening)</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Impulsive Aggression</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
</DOC>